Amgen (AMGN) Total Non-Current Liabilities (2009 - 2026)
Amgen's quarterly Total Non-Current Liabilities came in at $80.6 billion in Q1 2026, little changed year-on-year from $81.0 billion in Q1 2025, and up 1.26% quarter-over-quarter from $79.6 billion in Q4 2025.
Amgen has reported Total Non-Current Liabilities for 18 years, with the latest figure at $80.6 billion in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities changed 0.49% year-over-year to $80.6 billion; the trailing twelve-month figure through Mar 2026 stood at $80.6 billion (changed 0.49% YoY), and the FY2025 full-year result was $79.6 billion, down 4.86% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $80.6 billion, up from $79.6 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $87.9 billion in Q1 2024, with the low at $51.3 billion in Q2 2022.
- Average Total Non-Current Liabilities over 5 years is $76.0 billion, with a median of $81.0 billion recorded in 2025.
- Year-over-year, Total Non-Current Liabilities surged 62.35% in 2023 and declined 7.94% in 2025.
- Tracing AMGN's Total Non-Current Liabilities over 5 years: stood at $61.2 billion in 2022, then jumped by 40.94% to $86.2 billion in 2023, then retreated by 3.05% to $83.6 billion in 2024, then retreated by 4.86% to $79.6 billion in 2025, then advanced by 1.26% to $80.6 billion in 2026.
- The last three Total Non-Current Liabilities figures came in at $80.6 billion (Q1 2026), $79.6 billion (Q4 2025), and $78.3 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | 100.00 Mn |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 48.74 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 119.22 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 108.96 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 75.11 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 80.55 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 31.56 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 113.51 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 61.52 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 31.62 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 80.55 Bn |
| Dec 31, 2025 | 79.55 Bn |
| Sep 30, 2025 | 78.30 Bn |
| Jun 30, 2025 | 78.13 Bn |
| Mar 31, 2025 | 80.95 Bn |
| Dec 31, 2024 | 83.61 Bn |
| Sep 30, 2024 | 81.16 Bn |
| Jun 30, 2024 | 84.88 Bn |
| Mar 31, 2024 | 87.86 Bn |
| Dec 31, 2023 | 86.24 Bn |
| Sep 30, 2023 | 82.78 Bn |
| Jun 30, 2023 | 83.24 Bn |
| Mar 31, 2023 | 83.10 Bn |
| Dec 31, 2022 | 61.19 Bn |
| Sep 30, 2022 | 57.17 Bn |
| Jun 30, 2022 | 51.27 Bn |
| Mar 31, 2022 | 51.63 Bn |
| Dec 31, 2021 | 54.12 Bn |
| Sep 30, 2021 | 50.29 Bn |
| Jun 30, 2021 | 45.10 Bn |
| Mar 31, 2021 | 46.17 Bn |
| Dec 31, 2020 | 53.51 Bn |
| Sep 30, 2020 | 51.92 Bn |
| Jun 30, 2020 | 46.80 Bn |
| Mar 31, 2020 | 44.07 Bn |
| Dec 31, 2019 | 49.97 Bn |
| Sep 30, 2019 | 40.69 Bn |
| Jun 30, 2019 | 40.72 Bn |
| Mar 31, 2019 | 44.30 Bn |
| Dec 31, 2018 | 53.84 Bn |
| Sep 30, 2018 | 44.15 Bn |
| Jun 30, 2018 | 44.01 Bn |
| Mar 31, 2018 | 46.38 Bn |
| Dec 31, 2017 | 45.61 Bn |
| Sep 30, 2017 | 45.37 Bn |
| Jun 30, 2017 | 77.94 Bn |
| Mar 31, 2017 | 76.37 Bn |
| Dec 31, 2016 | 45.33 Bn |
| Sep 30, 2016 | 43.48 Bn |
| Jun 30, 2016 | 71.49 Bn |
| Mar 31, 2016 | 71.37 Bn |
| Dec 31, 2015 | 42.06 Bn |
| Sep 30, 2015 | 40.79 Bn |
| Jun 30, 2015 | 40.82 Bn |
| Mar 31, 2015 | 39.51 Bn |
| Dec 31, 2014 | 40.68 Bn |
| Sep 30, 2014 | 39.03 Bn |
| Jun 30, 2014 | 38.69 Bn |
| Mar 31, 2014 | 37.72 Bn |
| Dec 31, 2013 | 41.07 Bn |
| Sep 30, 2013 | 32.02 Bn |
| Jun 30, 2013 | 28.69 Bn |
| Mar 31, 2013 | 29.03 Bn |
| Dec 31, 2012 | 32.23 Bn |
| Sep 30, 2012 | 32.39 Bn |
| Dec 31, 2011 | 27.10 Bn |
| Mar 31, 2010 | 15.85 Bn |
| Dec 31, 2009 | 14.47 Bn |
| Sep 30, 2009 | 15.44 Bn |
| Jun 30, 2009 | 15.02 Bn |